Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.74 |
| ▸ | RAF1 | P04049 | 3/20 | 0.65 |
| ▸ | BRAF | P15056 | 3/20 | 0.65 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.65 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.65 |
| ▸ | PIM1 | P11309 | 1/20 | 0.65 |
| ▸ | PRKACA | P17612 | 1/20 | 0.65 |
| ▸ | LTK | P29376 | 1/20 | 0.65 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.65 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.65 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.65 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.65 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.65 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.65 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.65 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12087754 | 0.87 | EGFR (0.71) | EGFRRAF1BRAFABCG2AURKB | |
| SCHEMBL5239599 | 0.86 | EGFR (0.80) | EGFRRAF1BRAFAURKBRET | |
| SCHEMBL5845291 | 0.85 | EGFR (1.00) | EGFRABCG2ABL1ERBB2MAPK14 | |
| SCHEMBL8871418 | 0.85 | EGFR (0.71) | EGFRERBB2RETKDRHTT | |
| SCHEMBL5845413 | 0.85 | EGFR (0.72) | EGFRRAF1ABL1ERBB2MAPK14 | |
| SCHEMBL13604745 | 0.84 | EGFR (0.82) | EGFRRAF1BRAFAURKBRET | |
| SCHEMBL28748550 | 0.84 | EGFR (0.72) | EGFRRAF1BRAFABCG2AURKB | |
| SCHEMBL13599953 | 0.84 | RAF1 (0.79) | EGFRRAF1BRAFABCG2AURKB | |
| SCHEMBL13404529 | 0.84 | EGFR (0.64) | EGFRRAF1BRAFAURKBERBB2 | |
| SCHEMBL5010953 | 0.83 | FBP1 (0.74) | EGFRRAF1BRAFABCG2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-9452220-B2 | Coupling compounds of NSAID anti-inflammatory and analgesic drugs and EGFR kinase inhibitors, synthesis methods and applications thereof | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2016-09-27 | — | — | US | disclosed |
| US-20160175453-A1 | COUPLING COMPOUNDS OF NSAID ANTI-INFLAMMATORY AND ANALGESIC DRUGS AND EGFR KINASE INHIBITORS, SYNTHESIS METHODS AND APPLICATIONS THEREOF | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2016-06-23 | — | — | US | disclosed |
| CN-103483275-B | The coupling compound of NSAID class anti-inflammatory analgesic medicine and EGFR kinase inhibitor and synthetic method thereof and application | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2015-09-02 | — | — | CN | disclosed |
| CN-103483275-A | Coupling compound of NSAID anti-inflammatory pain killers and EGFR kinase inhibitor and synthetic method and application of coupling compound | GUANGZHOU INST BIOMED & HEALTH | 2014-01-01 | — | — | CN | disclosed |
| EP-2348020-A1 | Preparation process of erlotinib | Esteve Química, S.A. (ES) | 2011-07-27 | — | — | EP | disclosed |
| WO-2011076813-A1 | PREPARATION PROCESS OF ERLOTINIB | Esteve Química, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | HENNEQUIN LAURENT FRANCOIS AND | 2009-12-17 | — | — | US | disclosed |
| US-7569577-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-08-04 | — | — | US | disclosed |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-20070032513-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | EGFR, ERBB2, ERBB4 | EGFR 1/4885RAF1 18/4885BRAF 19/4885 |
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ERBB2, ABL1, EGFR | EGFR 3/4885RAF1 37/4885BRAF 63/4885 |
| US-20070032513-A1 | Quinazoline derivatives | ERBB2, EGFR, ABL1 | EGFR 2/4885RAF1 55/4885BRAF 75/4885 |
| US-20160175453-A1 | COUPLING COMPOUNDS OF NSAID ANTI-INFLAMMATORY AND ANALGESIC DRUGS AND EGFR KINASE INHIBITORS, SYNTHESIS METHODS AND APPLICATIONS THEREOF | EGFR, CHUK, ERBB2 | EGFR 1/4885RAF1 542/4885BRAF 119/4885 |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ERBB2, ABL1, EGFR | EGFR 3/4885RAF1 46/4885BRAF 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.